ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Gabapentin

Also written as “gabapentin”, “gabapentin 600 mg” and “Gabapentin Extended Release tablets”.

Its studies are mostly in Sleep Initiation and Maintenance Disorders · Hot Flashes · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 8 companies.

Drug pageGabapentin: every studyMany companies study it; this page follows only the 44 they lead. All 334 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 28, 200744 company-led studies, 1 open or runningNext primary completion: Jan 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris201 open or runningphase 4since Sep 28, 2007Sep 8, 2005Jan 31, 2027phase 4 · NCT07813026
Depomedits history only80 open or runningphase 4since Jun 5, 2017Jun 8, 2006none ahead
Teva Pharmaceutical Industriesits history only60 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
Sun Pharmaceutical Industriesits history only40 open or runningno phasesince Oct 22, 2008Oct 22, 2008none ahead
GlaxoSmithKlineits history only20 open or runningphase 1since Sep 29, 2011Sep 29, 2011none ahead
Pharmaceutical Research Management srlits history only20 open or runningphase 3since Mar 18, 2016Mar 18, 2016none ahead
Nang Kuang Pharmaceuticalits history only10 open or runningphase 4since Feb 24, 2014Feb 24, 2014none ahead
Pfizerits history only10 open or runningphase 1since May 5, 2010May 5, 2010none ahead

Also a collaborator on its studies: Chiltern International and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Sep 8, 2005.

  1. Dec 21, 2007Phase 4 study in Renal InsufficiencyNCT00584779 · 8 enrolled · Japan
  2. Jan 16, 2008Phase 3 study in Epilepsies, PartialNCT00603473 · 92 enrolled · Japan
  3. Feb 11, 2008Phase 3 study in Epilepsies, PartialNCT00620555 · 65 enrolled · Japan
  4. Mar 25, 2008Phase 4 study in Diabetic NeuropathiesNCT00644748 · 95 enrolled · Brazil
  5. Apr 1, 20085 phase 3 studies in Sleep Initiation and Maintenance DisordersNCT00659100, NCT00667108, NCT00666939 and 2 more
  6. Apr 23, 2008Phase 4 study in Sleep Initiation and Maintenance DisordersNCT00666796 · 20 enrolled · United States
  7. May 6, 2008Phase 3 study in Sleep Initiation and Maintenance DisordersNCT00674752 · 377 enrolled · United States
  8. Nov 3, 2008Phase 4 study in Renal InsufficiencyNCT00785772 · 1 enrolled · Japan
  9. Sep 30, 2009Phase 1 study in HealthyNCT00987779 · 26 enrolled · Singapore
  10. Jun 25, 2013Phase 3 study in Sleep Initiation and Maintenance DisordersNCT01888497 · 59 enrolled · United States
  11. Sep 24, 2020Phase 4 study in Abuse PotentialNCT04570436 · 52 enrolled · United States
  12. Mar 8, 2022Phase 4 study in Abuse PotentialNCT05319756 · 54 enrolled · United States
  13. Aug 17, 2026Phase 4 study in Healthy Non-dependent, Recreational Sedative UsersNCT07777965 · 44 enrolled · United States
  14. Sep 4, 2026Phase 4 study in HealthyNCT07813026 · 60 planned · United States

Ahead

  1. Jan 31, 2027Primary completion: phase 4 study in HealthyNCT07813026

TargetBeta

“Voltage-gated calcium channel modulator”ChEMBL 37, by rule

Other programs on the same 26 targets

ProgramCompanyFurthest phaseStudies
PregabalinruleViatrisphase 4149

Studies

All 20 Viatris leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07813026Healthy · United States4RecruitingJan 31, 202760
NCT07777965Healthy Non-dependent, Recreational Sedative Users · United States4CompletedAug 31, 202644
NCT05319756Abuse Potential · United States4CompletedDec 31, 202154
NCT04570436Abuse Potential · United States4CompletedNov 10, 202252
NCT01888497Sleep Initiation and Maintenance Disorders · United States3CompletedDec 14, 201359
NCT00987779Healthy · Singapore1CompletedOct 200926
NCT00785772Renal Insufficiency · Japan4TerminatedApr 20101
NCT00674752Sleep Initiation and Maintenance Disorders · United States3Completed377
NCT00667108Sleep Initiation and Maintenance Disorders · United States3Completed784
NCT00666939Sleep Initiation and Maintenance Disorders · United States3Completed773
NCT00666796Sleep Initiation and Maintenance Disorders · United States4Completed20
NCT00666770Sleep Initiation and Maintenance Disorders · United States3Completed309
NCT00666575Sleep Initiation and Maintenance Disorders · United States3Completed2,105
NCT00659100Sleep Initiation and Maintenance Disorders · United States3Completed1,254
NCT00644748Diabetic Neuropathies · Brazil4Completed95
NCT00620555Epilepsies, Partial · Japan3CompletedDec 201065
NCT00603473Epilepsies, Partial · Japan3CompletedDec 200992
NCT00584779Renal Insufficiency · Japan4TerminatedDec 20078
NCT00537940Epilepsy · Costa Rica, El Salvador, Guatemala and more4CompletedJul 2013482
NCT00163046Sleep Initiation and Maintenance Disorders · United States3Completed256

How it is read

Names in the registry

  • “Gabapentin”, 27 entries
  • “gabapentin”, 5 entries
  • “gabapentin 600 mg”, 3 entries
  • “Gabapentin Extended Release tablets”, 3 entries
  • “Gabapentin 800 mg tablets, single dose (1 tablet)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.